Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:38pm, Friday, 10'th May 2024
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
06:36pm, Thursday, 09'th May 2024
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.85 per share a year ago.
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
04:05pm, Thursday, 09'th May 2024
Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant ( CRN 0 4894 ) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing's Syndrome Will be Presented at ENDO June
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
04:05pm, Thursday, 02'nd May 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 11'th Apr 2024
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted
Under-the-radar biotech bets
01:47pm, Wednesday, 03'rd Apr 2024
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
12:51pm, Wednesday, 20'th Mar 2024
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
06:15am, Wednesday, 20'th Mar 2024
Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could b
Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win
08:08am, Tuesday, 19'th Mar 2024
Biotech stock Crinetics Pharmaceuticals rocketed early Tuesday after solid trial results for its oral growth hormone treatment.
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study
06:09am, Tuesday, 19'th Mar 2024
Crinetics Pharmaceuticals said on Tuesday its experimental drug to treat a hormonal disorder met the main goal in a late-stage study.
56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
04:05pm, Tuesday, 12'th Mar 2024
Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 11'th Mar 2024
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
02:20pm, Thursday, 29'th Feb 2024
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript
05:46am, Thursday, 29'th Feb 2024
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript
